Korea's toxin and skin-booster export trade is now consensus, and the targets say so

Hugel reported its best first half on rising botulinum toxin exports, and PharmaResearch set record quarterly revenue and operating profit on European sales of its Rejuran skin booster plus cosmetics exports ^[2][3]. Within days, at least five brokerages apiece raised their target prices ^[5][13], which tells you the export thesis on Korean aesthetic medicine is no longer a differentiated view but the house position at most desks covering these names.

Start with Hugel's arithmetic, because it is less flattering than the headline. First-half revenue was 254.5 billion won and operating profit 103.7 billion won, up 27.2% and 8.4%, both records ^[6]. That gap is margin: 40.7% in the first half against 47.8% a year earlier, roughly seven points of compression ^[1]. Second-quarter revenue rose 25.1% to 137.9 billion won while operating profit fell 1.1%, which Hugel attributes to upfront spending on a direct sales system in the United States ^[7]. Toxin revenue of 149.4 billion won, up 46.6%, did the work ^[8]: it was 58.7% of first-half sales ^[2], and everything else in the portfolio grew about 7.0% ^[3]. Sales in the Americas more than doubled on the U.S. and Brazil, with Asia-Pacific and Europe in the mid- to high 20% range ^[9].

PharmaResearch has the cleaner mix shift. Second-quarter revenue was 178.7 billion won and operating profit 66.5 billion won, up 27.1% and 19.0% ^[15]. Exports rose 62% to 84 billion won, or 47% of revenue ^[16], against roughly 36.9% a year earlier ^[5]. Cosmetics exports surged 124% to 43.6 billion won ^[18] while medical device exports rose 33% to 32.2 billion won on Rejuran, a polynucleotide skin booster derived from salmon DNA, in Europe ^[17]. Those two lines are about 90% of exports ^[6], and cosmetics is now roughly 1.35 times the size of device exports after being the smaller of the two a year ago ^[7]. Operating margin still slipped, to 37.2% from 39.8% ^[4].

Now the target prices, per FnGuide data cited by the Seoul Economic Daily. The 14 brokerages covering Hugel average 391,429 won, 52.9% above the 256,000 won close on the 14th ^[4]. The 14 covering PharmaResearch average 506,429 won, 27.2% above a 398,000 won close ^[12]. Hugel's implied upside is roughly double PharmaResearch's ^[10], and in both cases the averages lag the fresh work: the five disclosed post-results Hugel revisions average 408,000 won, 4.2% above consensus ^[8], and the six on PharmaResearch average 518,333 won, 2.4% above ^[9]. Consensus is being dragged up, not down.

Both sell-side arguments rest on the same quarter. Kim Ji-eun of DB Financial Investment said Hugel had confirmed the earnings capacity to absorb its U.S. direct sales investment through top-line growth, and that direct sales plus strong exports beginning in the third quarter should improve margins ^[11]. Cho Eun-ae of IBK Investment & Securities forecast that export growth would sustain quarter-on-quarter earnings growth for PharmaResearch in the third quarter ^[19]. Second-half export growth is expected to be led by China and North America ^[10].

So the tests are specific. For Hugel, whether third-quarter margin actually recovers as the U.S. organisation shifts from cost to channel ^[11][20]; the build cost is the flagged offset ^[21]. For PharmaResearch, whether a 124% cosmetics export line is a base effect or a run rate ^[18]. If neither converts, the 52.9% gap closes from the target side.